Daniel J. Lippis - 09 Jan 2026 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP, TAVR
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
09 Jan 2026
Net transactions value
-$26,949
Form type
4
Filing time
09 Jan 2026, 17:41:32 UTC
Previous filing
12 Dec 2025
Next filing
17 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lippis Daniel J. CVP, TAVR ONE EDWARDS WAY, IRVINE Linda J. Park, Attorney-in-Fact 09 Jan 2026 0002004380

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $60,383 +1,019 +4.6% $59.26 23,021 09 Jan 2026 Direct F1
transaction EW Common Stock Sale $87,332 -1,019 -4.4% $85.70 22,002 09 Jan 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -1,019 -20% $0.000000 4,076 09 Jan 2026 Common Stock 1,019 $59.26 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025.
F2 This transaction was executed in multiple trades at prices ranging from $85.45 to $85.95. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of theIssuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.